Jasper Therapeutics, Inc.
JSPR· Nasdaq
Released Mar 8, 2023, after the close
10-K filed Mar 8, 2023, 67 days after period end · 0001213900-23-018542
derived · Computed from the longer spans the company filed.
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures |
|---|---|---|---|
| Net Income | -$13.21M | -$9.06M | -$29.46M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Jasper Therapeutics, Inc. · CIK 1788028 · Engraved from SEC EDGAR
ended Dec 31, 2022 · filed Mar 8, 2023 · 67 d after period end
7.0% from the close of Mar 8, 2023 to the close of Mar 9, 2023, the first after the release.